Methods and compositions for reducing the risk of cardiovascular, cerebrovascular, or renovascular adverse events are provided. Generally, the methods include administering to a subject taking an NSAID a therapeutically effective amount of a misoprostol compound. The methods can also include administering to a subject in need thereof a therapeutically effective amount of an NSAID and therapeutically effective amount of a misoprostol compound.

Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof wherein Q, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein.

##STR00001##

The present invention relates to methods of treating neuropathy patients who have been administered a gabapentinoid. In particular, the methods involve administering a nucleic acid construct encoding human HGF proteins after discontinuing gabapentinoid. The present invention provides a novel method for a specific patient population to achieve a better therapeutic outcome by avoiding interference of therapeutic effects by gabapentinoids.

The present invention relates to methods of treating neuropathy patients who have been administered a gabapentinoid. In particular, the methods involve administering a nucleic acid construct encoding human HGF proteins after discontinuing gabapentinoid. The present invention provides a novel method for a specific patient population to achieve a better therapeutic outcome by avoiding interference of therapeutic effects by gabapentinoids.

The invention provides compounds of Formula XXIII:

##STR00001##

wherein R.sub.1 is hydrogen, alkyl, acyl, or silyl, R.sub.2 is hydrogen, alkyl, benzyl, acyl, or ester, and R.sub.3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.

The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.

The present application provides bifunctional compounds of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 9 (CDK9). the present application also relates to methods for the targeted degradation of CDK9 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK9 which can be utilized in the treatment of disorders modulated by CDK9.

The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO.sub.2, amino, COOH, COOCH.sub.3, OH, N.sub.3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O, Bn- optionally substituted, or Ph- optionally substituted. ##STR00001##

The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.